◎ Sugi Atlas

Atlas / Drug / Bazedoxifene

Bazedoxifene

drug
On this page

Also known as Bazedoxifene component of ak r215Bazedoxifene component of ak-r215BazedoxifenoBazedoxifene HCl

Summary

Bazedoxifene (CHEMBL46740) is an approved small molecule (ATC G03XC02) targeting ESR1 and ESR2; indicated across 5 conditions including osteoporosis and postmenopausal osteoporosis; with CIViC clinical evidence for 2 variant-indication associations (e.g. PIK3CA Mutation in breast carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: G03XC02
  • Targets: 2 (ESR1, ESR2)
  • Indications: 5 conditions
  • Clinical trials: 30
  • Precision-oncology evidence (CIViC): 2 variant–indication associations
  • Chemistry: 470.6 Da · C30H34N2O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL46740
NameBazedoxifene
TypeSmall molecule
Max phase4
FDA approvedno
PubChem CID154257
ATCG03XC02
Molecular formulaC30H34N2O3
Molecular weight470.6
InChIKeyUCJGJABZCDBEDK-UHFFFAOYSA-N

SMILES: CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O

IUPAC name: 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol

Also known as: Bazedoxifene, Bazedoxifene component of ak r215, Bazedoxifene component of ak-r215, Bazedoxifeno, BAZEDOXIFENE, bazedoxifene, Bazedoxifene HCl

Parent form; salt/anhydrous children: CHEMBL2106615

Patent coverage: 1,503 distinct patent families (5,052 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 4,458 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ESR1Estrogen receptor-αAntagonist7.641.7%P03372
ESR2Estrogen receptor-βAntagonist7.070.2%Q92731

Broader ChEMBL bioactivity targets: 30 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Sodium channel protein type 5 subunit alpha, Glucocorticoid receptor, D(1A) dopamine receptor, Estrogen receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 33 potent at pChembl ≥ 5 of 43 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ESR19.22IC500.6nMCHEMBL_ACT_1654157
ESR18.43IC503.7nMCHEMBL_ACT_1001021
ESR28.42IC503.8nMCHEMBL_ACT_1654158
ESR17.64IC5023nMCHEMBL_ACT_1001019
ESR17.64IC5023nMCHEMBL_ACT_26151150
ESR17.3IC5050nMCHEMBL_ACT_17643869
ESR17.3IC5050nMCHEMBL_ACT_26584238
ESR27.07IC5085nMCHEMBL_ACT_1001020
ESR27IC5099nMCHEMBL_ACT_26151151
ESR16.71AC50197nMCHEMBL_ACT_25116299
ADRA2C6.65AC50225.8nMCHEMBL_ACT_25147654
SLC6A26.58AC50260nMCHEMBL_ACT_25144783
ESR16.47IC50339.2nMCHEMBL_ACT_25718828
HTR2B6.2AC50631nMCHEMBL_ACT_25164047
PTGS26.06AC50870nMCHEMBL_ACT_25165978
ADRA1A5.96AC501090nMCHEMBL_ACT_25138380
GHSR5.96AC501100nMCHEMBL_ACT_25172542
KCNH25.85AC501400nMCHEMBL_ACT_25117546
Q639215.85AC501400nMCHEMBL_ACT_25174182
HTR2A5.72AC501900nMCHEMBL_ACT_25224978
HRH35.66AC502200nMCHEMBL_ACT_25200416
ADRA2A5.64AC502301nMCHEMBL_ACT_25219689
SLC6A45.57AC502700nMCHEMBL_ACT_25150121
SLC6A35.54AC502900nMCHEMBL_ACT_25123733
HTR2B5.54AC502900nMCHEMBL_ACT_25227323
ADRA2B5.5AC503200nMCHEMBL_ACT_25143485
DRD25.33AC504700nMCHEMBL_ACT_25140111
ADORA35.23AC505900nMCHEMBL_ACT_25133992
CHRM25.19AC506500nMCHEMBL_ACT_25213532
OPRM15.17AC506700nMCHEMBL_ACT_25157299

Target pathways

Aggregated over 2 target gene(s): ESR1, ESR2.

Top Reactome pathways

17 total, by targets touching each:

PathwayTargetsGenes
PIP3 activates AKT signaling2ESR1, ESR2
Constitutive Signaling by Aberrant PI3K in Cancer2ESR1, ESR2
Nuclear Receptor transcription pathway2ESR1, ESR2
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling2ESR1, ESR2
ESR-mediated signaling2ESR1, ESR2
Extra-nuclear estrogen signaling2ESR1, ESR2
Nuclear signaling by ERBB41ESR1
SUMOylation of intracellular receptors1ESR1
Ovarian tumor domain proteases1ESR1
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors1ESR1
RUNX1 regulates estrogen receptor mediated transcription1ESR1
RUNX1 regulates transcription of genes involved in WNT signaling1ESR1
Regulation of RUNX2 expression and activity1ESR1
Estrogen-dependent gene expression1ESR1
Mitochondrial unfolded protein response (UPRmt)1ESR1
Developmental Lineage of Mammary Gland Luminal Epithelial Cells1ESR1
Developmental Lineage of Mammary Gland Alveolar Cells1ESR1

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II2
regulation of DNA-templated transcription2
regulation of transcription by RNA polymerase II2
signal transduction2
estrogen receptor signaling pathway2
positive regulation of DNA-templated transcription2
positive regulation of transcription by RNA polymerase II2
obsolete positive regulation of DNA-binding transcription factor activity2
cellular response to estradiol stimulus2
cellular response to oxygen-containing compound2
antral ovarian follicle growth1
epithelial cell development1
chromatin remodeling1
phospholipase C-activating G protein-coupled receptor signaling pathway1
positive regulation of cytosolic calcium ion concentration1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
osteoporosis3MONDO:0005298EFO:0003882
postmenopausal osteoporosis2MONDO:0008159EFO:0003854
ductal breast carcinoma in situ2MONDO:0005023EFO:0000432
breast neoplasm2MONDO:0021100MONDO:0007254

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 30.

Phase distribution

PhaseTrials
PHASE111
PHASE37
PHASE44
Not specified4
PHASE23
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02090400PHASE4COMPLETEDSwitching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women
NCT02237079PHASE4COMPLETEDBazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)
NCT02602704PHASE4COMPLETEDEffectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients
NCT03740009PHASE4COMPLETEDEffects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause
NCT00234819PHASE3COMPLETEDStudy Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
NCT00238732PHASE3COMPLETEDStudy Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
NCT00242710PHASE3COMPLETEDStudy Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
NCT00384072PHASE3COMPLETEDStudy Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
NCT00481169PHASE3COMPLETEDStudy Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
NCT00675688PHASE3COMPLETEDStudy Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
NCT00808132PHASE3COMPLETEDStudy Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
NCT04821141PHASE2ACTIVE_NOT_RECRUITINGPhase IIB Trial of Bazedoxifene Plus Conjugated Estrogens
NCT00238745PHASE2COMPLETEDStudy Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis.
NCT02448771PHASE1/PHASE2COMPLETEDA Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer
NCT02694809PHASE2COMPLETEDThe PROMISE Study: Duavee in Women With DCIS
NCT00367536PHASE1COMPLETEDStudy Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution
NCT00396799PHASE1COMPLETEDBioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women
NCT00465075PHASE1COMPLETEDStudy Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women
NCT00479778PHASE1COMPLETEDStudy Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms
NCT00550303PHASE1COMPLETEDStudy Comparing Formulations of Bazedoxifene/Conjugated Estrogens
NCT00550433PHASE1COMPLETEDStudy Evaluating Bazedoxifene/CE in Postmenopausal Women
NCT00706225PHASE1COMPLETEDStudy Evaluating Potential Drug Interaction Of Bazedoxifene & Premarin In Healthy Postmenopausal Women
NCT01634789PHASE1TERMINATEDA Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women
NCT03234244PHASE1COMPLETEDHDDO-1614 Intervention Trial
NCT03321318PHASE1UNKNOWNAK-R215 Pharmacokinetic Study Phase I
NCT03382314PHASE1COMPLETEDHDDO-1614 Bio Equivalence Study
NCT00847821Not specifiedTERMINATEDObservational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene
NCT01416194Not specifiedCOMPLETEDBazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)
NCT01470326Not specifiedCOMPLETEDViviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)
NCT04812808Not specifiedUNKNOWNBazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma

Clinical evidence (CIViC)

Variant × indication × effect (2 predictive associations from 2 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
PIK3CA MutationBreast CarcinomaSensitivity/ResponsePalbociclib Regimen + BazedoxifeneCIViC BEID12619
IL6 OverexpressionRhabdomyosarcomaResistanceBazedoxifeneCIViC DEID7956

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

178 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FULVESTRANTChEMBL + PubChemPhase 4 (approved)ESR1, ESR2
BITHIONOLChEMBLPhase 4 (approved)ESR1, ESR2
CISPLATINChEMBLPhase 4 (approved)ESR1, ESR2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)ESR1, ESR2
ELACESTRANTChEMBLPhase 4 (approved)ESR1, ESR2
ESTETROLChEMBLPhase 4 (approved)ESR1, ESR2
ESTRADIOLChEMBLPhase 4 (approved)ESR1, ESR2
ESTRIOLChEMBLPhase 4 (approved)ESR1, ESR2
ESTRONEChEMBLPhase 4 (approved)ESR1, ESR2
ETHINYL ESTRADIOLChEMBLPhase 4 (approved)ESR1, ESR2
HEXACHLOROPHENEChEMBLPhase 4 (approved)ESR1, ESR2
LASOFOXIFENEChEMBLPhase 4 (approved)ESR1, ESR2
MEDROXYPROGESTERONEChEMBLPhase 4 (approved)ESR1, ESR2
MIFEPRISTONEChEMBLPhase 4 (approved)ESR1, ESR2
PHENOLPHTHALEINChEMBLPhase 4 (approved)ESR1, ESR2
RALOXIFENEChEMBLPhase 4 (approved)ESR1, ESR2
SPIRONOLACTONEChEMBLPhase 4 (approved)ESR1, ESR2
TAMOXIFENChEMBLPhase 4 (approved)ESR1, ESR2
ACOLBIFENEChEMBLPhase 3ESR1, ESR2
AFIMOXIFENEChEMBLPhase 3ESR1, ESR2
AMCENESTRANTChEMBLPhase 3ESR1, ESR2
ARZOXIFENEChEMBLPhase 3ESR1, ESR2
BENSERAZIDEChEMBLPhase 3ESR1, ESR2
ALFATRADIOLChEMBLPhase 2ESR1, ESR2
AUS-131ChEMBLPhase 2ESR1, ESR2
BRILANESTRANTChEMBLPhase 2ESR1, ESR2
DAIDZEINChEMBLPhase 2ESR1, ESR2
ERTEBERELChEMBLPhase 2ESR1, ESR2
GENISTEINChEMBLPhase 2ESR1, ESR2
GTX-758ChEMBLPhase 2ESR1, ESR2
IDOXIFENEChEMBLPhase 2ESR1, ESR2
LEVORMELOXIFENEChEMBLPhase 2ESR1, ESR2
MOXESTROLChEMBLPhase 2ESR1, ESR2
PIPENDOXIFENEChEMBLPhase 2ESR1, ESR2
PRINABERELChEMBLPhase 2ESR1, ESR2
STALLIMYCINChEMBLPhase 2ESR1, ESR2
BosentanPubChemApprovedESR1, ESR2
DihydroergotaminePubChemApprovedESR1, ESR2
FidaxomicinPubChemApprovedESR1, ESR2
PropoxyphenePubChemApprovedESR1, ESR2
PyrazinamidePubChemApprovedESR1, ESR2
ACETOPHENAZINEChEMBLPhase 4 (approved)ESR1
ALECTINIBChEMBLPhase 4 (approved)ESR1
APOMORPHINEChEMBLPhase 4 (approved)ESR1
ARIPIPRAZOLEChEMBLPhase 4 (approved)ESR1
ASPIRINChEMBLPhase 4 (approved)ESR1
AZTREONAMChEMBLPhase 4 (approved)ESR1
BELINOSTATChEMBLPhase 4 (approved)ESR1
BENZBROMARONEChEMBLPhase 4 (approved)ESR1
BEXAROTENEChEMBLPhase 4 (approved)ESR1
BISACODYLChEMBLPhase 4 (approved)ESR1
BROMOCRIPTINEChEMBLPhase 4 (approved)ESR1
BUTOCONAZOLEChEMBLPhase 4 (approved)ESR1
CANDESARTAN CILEXETILChEMBLPhase 4 (approved)ESR1
CASPOFUNGINChEMBLPhase 4 (approved)ESR1
CEFADROXILChEMBLPhase 4 (approved)ESR1
CEFEPIMEChEMBLPhase 4 (approved)ESR1
CEFTAZIDIMEChEMBLPhase 4 (approved)ESR1
CERIVASTATINChEMBLPhase 4 (approved)ESR1
CHLOROTRIANISENEChEMBLPhase 4 (approved)ESR1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot